| Business Summary | | Genzyme
Molecular
Oncology,
a
division
of
Genzyme
Corporation,
is
developing
a
new
generation
of
cancer
therapeutics
based
upon
the
growing
understanding
of
the
molecular
basis
of
cancer.
These
therapeutics
are
expected
to
potentially
treat
multiple
types
of
cancer,
minimize
toxicity
and
side
effects,
and
complement
both
existing
and
novel
therapies.
Genzyme
Molecular
Oncology
supplements
its
internal
resources
through
collaborations
with
scientists
and
clinicians
in
the
field
of
cancer.
Genzyme
Molecular
Oncology
is
developing
products
primarily
focused
on
vaccines
that
treat
cancer
by
stimulating
the
body's
immune
system
to
fight
tumor
cells
and
angiogenesis
inhibitors
that
treat
cancer
by
preventing
the
formation
and
development
of
blood
vessels
that
tumors
require
for
growth. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Genzyme
Molecular
Oncology
is
engaged
in
the
development
and
commercialization
of
novel
cancer
products
focusing
on
cancer
vaccines
and
angiogenesis
and
inhibitors.
For
the
six
months
ended
6/30/01,
revenues
decreased
24%
to
$2.7
million.
Net
loss
increased
18%
to
$14.6
million.
Revenues
reflect
the
absence
of
a
product
development
milestone
payment
from
Schering-Plough
Ltd.
Net
loss
was
partially
offset
by
the
absence
of
a
$5.4
million
amortization
of
intangibles
expense. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Henri Termeer, 55 Chairman,
Pres and CEO | $1.9M | Michael Wyzga, 46 CFO,
Chief Accounting Officer, Sr. VP-Fin. | -- | Earl Collier, Jr., 53 Exec.
VP; Pres, Genzyme Biosurgery | 814K | G. Jan Van Heek, 51 Exec.
VP of Therapeutics and Genetics | 649K | Peter Wirth, 50 CLO,
Exec. VP of Corp. Devel. and Clerk | 772K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|